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Abstract
Researchers studying fibromyalgia strive to identify objective,
measurable biomarkers that may identify susceptible individuals,
may facilitate diagnosis, or that parallel activity of the disease.
Candidate objective measures range from sophisticated functional
neuroimaging to office-ready measures of the pressure pain
threshold. A systematic literature review was completed to assess
highly investigated, objective measures used in fibromyalgia
studies. To date, only experimental pain testing has been shown to
coincide with improvements in clinical status in a longitudinal
study. Concerted efforts to systematically evaluate additional
objective measures in research trials will be vital for ongoing
progress in outcome research and translation into clinical practice.
Introduction
Fibromyalgia (FM) is a chronic condition characterized by
widespread pain and tenderness on examination, along with
symptoms of nonrestorative sleep, fatigue, and cognitive
difficulties. Recent familial studies have suggested an
underlying genetic susceptibility on which environmental
factors trigger the expression of symptoms [1,2]. Despite the
myalgias that patients experience, no abnormality in muscle
has been reliably found [3]. Instead, aberrant pain and sen-
sory processing probably caused by alterations in the central
nervous system function are being consistently recognized in
FM and related syndromes. Investigations into the autonomic
nervous system and the hypothalamic–pituitary–adrenal axis
also suggest a role of these stress–response systems in
vulnerability to FM or in symptom expression in FM.
Our improved understanding of FM has stimulated the search
for biomarkers to be used to identify individuals susceptible
to the syndrome, for the diagnosis of FM, for objective
measures of disease activity, or as surrogate endpoints of
clinical trials. Using an expert panel from the FM workshop of
the Outcome Measures in Rheumatology (OMERACT), a list
of potential objective measures was first developed. Studies
evaluating the measures were then methodically compiled by
systematic review of the literature using a search for FM and
the specific objective measure of interest. The databases
searched included MEDLINE (1966 to 2006), PubMed
(1966 to 2006), CINAHL (1982 to 2006), EMBASE (1988
to 2006), Healthstar (1975 to 2000), Current Contents
(2000 to 2006), Web of Science (1980 to 2006), PsychInfo
(1887 to 2006), Science Citation Indexes (1996 to 2006),
and/or Cochrane Collaboration Reviews (1993 to 2006). The
resulting published studies were used as the basis for the
review.
Genetics
Increasing evidence supports a genetic predisposition to FM.
First-degree relatives of individuals with FM display an
eightfold greater risk of developing the syndrome than those
in the general population [1]. As such, a genetic study using
multicase families has been completed that identified an HLA
linkage not yet replicated [4].
Polymorphisms in the serotonergic 5-hydroxy tryptamine 2A
receptor (T/T phenotype), the serotonin transporter, the
dopamine 4 receptor and the catecholamine o-methyl trans-
ferase enzyme have also been evaluated in patients with FM
[5-10]. Notably, these polymorphisms all affect the
metabolism or transport of monoamines, compounds that
have a critical role in both sensory processing and the human
stress response. With the exception of the catecholamine o-
methyl transferase finding and the dopamine-4-receptor gene
polymorphism, however, which have not been replicated or
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refuted, the other findings initially noted were generally not
found in subsequent studies [4-10]. In some cases, the
findings in FM were found when all individuals with this
disorder were studied, but not when individuals free of
psychiatric comorbidities were studied, suggesting that some
of the above findings may track more closely with psychiatric
comorbidity than inherent features of FM. Other candidate
genes evaluated but not shown to be associated with FM are
presented in Table 1.
Evoked (experimental) pain measures
Even before the establishment of the American College of
Rheumatology criteria for FM in 1990, which require both
widespread pain and tenderness, investigators have used
psychophysical pain testing to learn more about the nature of
this condition. In fact, the early findings that the tenderness in
FM was detectable throughout the body, rather than just
confined to areas of tender points or muscle, was a hallmark
finding that led investigators to believe this was a central
nervous system pain amplification syndrome [11]. These
measures are only relatively objective since they require patient
self-report, but tender points do clearly measure a pheno-
menon that is independent from spontaneous, clinical pain.
Numerous experimental pain studies have evaluated methods
of quantifying the sensory experience of pain. Various groups
using an assortment of devices that produce several stimuli
have assessed the pain threshold and have attempted to
quantify the pain experience in FM. A review of the investi-
gated modalities gives the greatest support for the use of the
tender point intensity/index, pressure pain thresholds, or heat
pain thresholds as objective measures of the degree of
hyperalgesia (increased pain to normally painful stimuli) and
allodynia (pain in response to normally nonpainful stimuli) of
an individual. Another consistent finding has been an
absence of descending endogenous analgesic activity in FM.
Tender point count
The American College of Rheumatology criteria for FM require
that an individual has a certain degree of tenderness. A
tender point count is performed by applying 4 kg pressure
manually to 18 predefined tender points, and then asking the
patient whether these areas are tender. A positive response
is considered a tender point; if an individual has 11 tender
points or more, this element of the case definition is satisfied.
The apparent close link between tenderness and FM has
been well studied in both clinical trials of new therapies and
in mechanistic studies. In a number of longitudinal rando-
mized, placebo-controlled trials, improvements in clinical pain
have corresponded with a significant change in tender point
counts or in the tender point index [12-14]. In contrast, other
studies did not show a correspondence between improve-
ments in clinical pain and tender point counts [15-20].
Table 1
Genetics in fibromyalgia
Number of 
Year of  Number of  control 
Reference study subjects individuals Objective measure Findings
Bondy and  1999 168 FMS 115 5-HT2A, T102C polymorphism Different from control, but not significant 
colleagues [5] for specific allele
Gürsoy and  2001 58 FMS 58 5-HT2A, T102C polymorphism Not significant
colleagues [6]
Gürsoy and  2003 61 FMS 61 COMT haplotype Over-representation of LL variant (low 
colleagues [7] activity). Similar to migraine and TMD
Offenbaecher  1999 62 FMS 110 5-HTT One positive for over-representative SS 
and colleagues [8] genotype, one negative study. Suggestion 
that any association might be related to 
comorbid psychology
Gürsoy [9] 2002 53 FMS 60 mentally  5-HTT
healthy
Yunus and  1999 40 multicase  HLA Linkage to HLA
colleagues [4] families
Buskila and  2004 Dopamine D4 receptor  Decrease in the frequency of the seven-
colleagues [10] polymorphism repeat allele in exon III of the D4 receptor 
gene associated with fibromyalgia. Finding 
associated with low novelty-seeking 
personality
COMT, catecholamine o-methyl transferase; FMS, fibromyalgia syndrome; 5-HT2A, serotonergic 5-hydroxytryptamine 2A receptor (T/T phenotype);
5-HTT, serotonin transporter; TMD, temporomandibular disorder.Page 3 of 18
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The discrepancies between studies could either be because
the therapies did not improve tenderness or because tender
points are not a good measure of tenderness. Both factors
are likely to play a role since, in certain studies where multiple
measures of the pain threshold were used, tender point
counts did not significantly improve whereas other measures
did [21,22]. Moreover, other studies have shown that tender
points are not a pure measure of tenderness. For example,
there is a strong correlation between tender point counts and
measures of distress in population-based studies [23].
Tender points have also been demonstrated to be biased by
cognitive and emotional aspects of pain perception, whereas
other measures of tenderness are much less so (see below)
[24]. Improvements in tender point counts in some previous
FM trials therefore possibly occurred because of improve-
ments in distress, rather than because of inherent improve-
ments in pressure pain threshold. Finally, tender points are
often not continuously distributed in samples; rather, most
people have either very few or nearly 18 tender points. As
such, many investigators do not feel that tender point counts
are useful to assess tenderness, and have instead turned to
psychophysically and statistically superior measures.
Pressure pain thresholds
Directly measuring pressure pain thresholds is an alternative
method of documenting tenderness. Devices that measure
pressure pain thresholds have been used to demonstrate a
left-shift and lowered pressure pain thresholds in patients
with FM compared with control individuals, and this finding is
noted anywhere in the body, both at tender points and in
areas previously considered control points (Table 2). These
findings suggest to many investigators that the term control
points should be abandoned, or replaced by a term such as
high-threshold tender point, since FM patients are just as
tender in these regions relative to healthy control individuals.
Many of these studies initially used commercial devices or
dolorimeters to deliver continuously increasing pressure via
blunt probes. These measures were found to be sensitive to
psychophysical and psychological biases, however, slightly
similar to tender point counts using digital palpation
(reviewed in [25]). For instance, the rate of increase of
stimulus pressure, controlled by the operator, and patient
distress were both shown to influence the pain threshold
[24,26]. To minimize the bias, more sophisticated paradigms
using random delivery of pressures have been developed and
investigated [27,28] (Table 3). Random delivery may be less
sensitive to certain influences, but it is not free of bias. For
instance, in a study by Petzke and colleagues, FM patients
reported higher pain during random delivery than during
ascending – possibly due to a perceived lack of control [28].
A recent longitudinal study compared the three different
evoked measures – tender point counts, the dolorimeter
(ascending pressure paradigm), and the multiple random
staircase (random pressure paradigm) – with clinical reports
of pain improvement [21]. Although both clinical pain
measures improved during the course of the study involving
acupuncture, only one of the evoked measures – the multiple
random staircase measure, which presented stimuli to
individuals in an unpredictable fashion – improved after
treatment. These results suggest that, of the different
methods, the random stimuli paradigm may be more likely to
systematically change over time. Interpretation of the results
is nonetheless limited and will need to be reproduced and
examined using other treatment modalities.
Heat, cold, and electrical stimuli
In addition to the heightened sensitivity to pressure noted in
FM, other types of painful stimuli also are judged more painful
by these patients. A decreased heat pain threshold in FM
patients as compared with control individuals has been
shown by multiple groups [28-30] (Table 4). A reduced cold
pain threshold has been reported by one group in two
different studies [30,31]. Sensitivity to warmth and the ability
to detect electrical stimuli do not appear to be discriminative
measures at this time.
Diminished diffuse noxious inhibitory control
In the process of understanding altered evoked pain sensi-
tivity present in FM, evaluation of the intrinsic analgesic
systems has uncovered another potential biomarker:
diminished diffuse noxious inhibitory control (DNIC). DNIC
testing in both animals and humans involves testing the pain
threshold at baseline, and then administering an acutely
painful stimulus that leads to a systemic analgesic effect,
presumably by activating endogenous analgesic systems.
Several studies by different groups, using different con-
ditioning stimuli (the acute noxious stimulus) and test stimuli
(the stimulus used to measure pain threshold at baseline and
following the acute, noxious stimulus), have indicated a
deficiency of DNIC in individuals with FM. Diminished DNIC
was observed in four cross-sectional studies by different
groups that used variable test and conditioning stimuli
[31,32-34] (Table 5). Diminished DNIC has also been noted
in other types of chronic pain; that is, temporomandibular
disorder and hip osteoarthritis [35,36]. The normalization of
DNIC after hip osteoarthritis surgery suggests it may be an
objective measure of chronic pain that can change over time
with treatment [36].
Functional neural imaging
Functional neural imaging enables investigators to visualize
how the brain processes the sensory experience of pain. The
primary modes of functional imaging that have been used in
FM include functional magnetic resonance imaging (fMRI),
single-photon emission computed tomography (SPECT), and
positron emission tomography.
fMRI studies evaluating pain processing have the strongest
current evidence of the functional imaging studies, because
Available online http://arthritis-research.com/content/10/4/211Arthritis Research & Therapy    Vol 10 No 4 Dadabhoy et al.
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Table 2
Pressure pain thresholds in fibromyalgia
Number Number 
Year of  of FM  of control  QST 
Reference study patients individuals QST method Findings
Staud and  2005 11 12 PPT: affected  ASC Decreased PPT (opposite of HC) after exercise
colleagues [102] and CP
Sandberg and  2005 19 19 HC, 7 TM PPT: TP ASC FM, TM with decreased PPT
colleagues [103]
Montoya and  2005 12 12 PPT, ERP ASC No difference (trend toward FM with decreased 
colleagues [104] PPT). HC with decreased PPTs with repeat stimuli 
in one session. Decreased PPT for left hand versus 
right hand. FM decreased PPT in second 
assessment period (after EEG)
Laursen and  2005 10 FM/whiplash,  41 PPT: TP  ASC FM/whiplash, RA, endometriosis, CLBP with 
colleagues [105] 2005 10 RA,  and CP decreased PPT. Correlation between pressure 
10 CLBP,  hyperalgesia at lowest PPT sites and physical 
10 endometriosis function impairment and mental health found
Landis and  2004 37 30 PPT: TP  ASC FM women with decreased PPT. PPT correlated 
colleagues [51] and CP with sleep spindle incidence and duration
Landis and  2004 33 37 PPT: TP ASC FM women with decreased PPT
colleagues [106]
Maquet and  2004 20 50 females,  PPT: TP ASC HC with decreased intraindividual variation (FM 
colleagues [107] 50 males w/24%). HC females with decreased PPT 
compared with HC males. FM with decreased PPT 
compared with HC females. No difference 
between dominant and nondominant hands. PPT 
reproducibility and discrimination optimal at gluteal 
and knee
Geisser and  2003 20 20 PPT: TP  ASC FM with decreased PPT (more statistically 
colleagues [108] and CP significant than HPT). Catastrophizing correlated 
with decreased PPT. Depression associated with 
increased PPT
Yoldas and  2003 11 10 PPT and  ASC FM reduced P300 amplitude, correlated well with 
colleagues [47] ERP PPT
Ernberg and 
colleagues [109] 2003 18 n/a PP: over  ASC No difference (trend toward decreased 
masseter PPT after antagonist)
Carli and  2002 145 (FM,  22 PPT: CP and TP,  ASC FM with decreased PPT (CFS, MPTE), HPT (CFS), 
colleagues [110] CFS, WP,  HPT, CPT, cold  cold pressor test (CFS), ischemic tourniquet test 
MPTE, MP) pressor test,  (CFS, MPTE, WP, MP) than HC
ischemic tourniquet 
test
Hedenberg-  2002 18 15 masseter  PPT: over  ASC Decreased PPT after treatment in both groups. 
Magnusson and colleagues [111] myalgia masseter Correlated with symptoms
Ernberg and  2000 12 12 HC,  PPT: masseter ASC FM with decreased PPT
colleagues [112] 12 RA
Graven-Nielsen  2000 15 FM  Placebo EPT, PPT:  ASC Increased PPT at TA muscle, pain pressure 
and colleagues [113] ketamine  TA muscle, PPT  tolerance after ketamine compared with placebo. 
responders and pain tolerance: 3 TPs Noted improvement in symptoms
Ernberg and  2000 12 12 PPT ASC FM with no significant increase in pain or decrease 
colleagues [114] in PPT. HC with increased pain and decrease in 
PPT after infusion
Ernberg and  1999 18 10 HC, 17  PPT, pain  ASC FM with decreased PPT associated with higher 
colleagues [115] local myalgia  tolerance:  fraction of masseter to serum serotonin levels
masseter
Continued overleafthey corroborate this left-shift in stimulus–response function
(that is, hyperalgesia/allodynia) noted in FM. Specifically,
several areas of the brain consistently show greater activation
in FM patients than in control individuals given the same
objective stimulus intensity – especially the secondary
somatosensory cortex, insula and the anterior cingulate
cortex. These findings have been noted in five cross-sectional
studies by two different groups, using both pressure and heat
stimuli [37,38] (Table 6). In the study by Giesecke and
colleagues, the clinical pain intensity corresponded with an
increase in the evoked regional cerebral blood flow [37]. The
resting regional cerebral blood flow was evaluated by a third
group in a longitudinal study using fMRI, and showed change
after drug treatment [39]. These studies have also been
useful in identifying differences in pain processing in
individuals with and without psychological comorbidities,
showing for example that depression does not seem to be
influencing the magnitude of neuronal activation in sensory
pain regions such as the secondary somatosensory cortex,
whereas cognitive factors such as catastrophizing did
influence the sensory intensity of pain [37,40].
Positron emission tomography imaging in FM has been
reported in only a few studies with inconclusive results. The
only positive study is a recent one showing there may be
altered dopaminergic activity in FM [41].
SPECT imaging has been studied in four cross-sectional
studies by different groups that consistently found reduced
regional cerebral blood flow in the right thalamus of patients
with FM (three of the four studies) [42-45]. No correlation
between symptoms and findings were noted in the SPECT
studies.
The consistent abnormalities seen in fMRI and SPECT
studies suggest either of these methods might be useful to
use as a biomarker, but longitudinal studies showing that
improvements in symptoms coincide with normalization of
functional imaging findings would be necessary to establish
this role. The advantages of fMRI imaging over positron
emission tomography and SPECT include the less invasive
nature and the higher temporal and spatial resolutions of
fMRI. Disadvantages of fMRI include the cost and prac-
Available online http://arthritis-research.com/content/10/4/211
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Table 2
Continued
Number Number 
Year of  of FM  of control  QST 
Reference study patients individuals QST method Findings
Kosek and  1997 10 10 PPT ASC FM decreased PPT
Hansson [30]
Kosek and  1996 10 10 PPT ASC FM decreased PPT
colleagues [31]
McDermid and  1996 20 20 HC,  PPT: TP  ASC FM decreased PT compared with RA, HC. RA 
colleagues [116] 20 RA and CP decreased PT compared with HC
Kosek and  1995 16 n/a PPT at  ASC No difference in PPT after EMLA cream
colleagues [117] cream site
Tunks and  1995 6 6 myofascial  PPT: TP  ASC FM and myofascial pain was discriminated from 
colleagues [118] 1995 6 pain controls,  and CP HC by dolorimetry and palpation
6 HC
Wolfe and  1995 391 n/a TPC,  ASC PPT and TPC correlate with symptoms, but TPC 
colleagues [119] dolorimetry correlates better
Gibson and  1994 10 10 PPT: TP  ASC FM decreased PPT at CT and TP, but data not 
colleagues [29] and CP  clearly shown
Lautenbacher and  1994 26 26 PPT: CP  ASC FM decreased PPT
colleagues [120] and TP
Granges and  1993 60 60 PPT: TP  ASC FM decreased HPT, PPT, CPT in CP and TP
Littlejohn [121] and CP
Lautenschlager and  1991 47 n/a PPT: TP  ASC Body diagram correlated better with dolorimetric 
colleagues [122] and CP findings than visual analog scale
ASC, ascending; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; CP, control point; CPT, cold pain threshold; CT, cold perception
threshold; EEG, electroencephalography; EMLA, local anesthetic cream; EPT, electrical pain threshold; ERP, event-related potential; FM, fibro-
myalgia; HC, healthy control individuals; HPT, heat pain threshold; MP, diffuse multiregional pain; MPTE, multiregional pain associated with at least
11 tender points; n/a, not applicable; PPT, pain pressure thresholds; QST, quantitative sensory testing; RA, rheumatoid arthritis; TA, tibialis
anterior; TM, temporal mandibular disorder; TP, tender point; TPC, tender point count; WP, widespread pain.ticability as well as the inability to perform receptor–ligand
studies that are possible with positron emission tomography
and SPECT.
Event-related potentials
Cerebral potentials evoked by noninvasive stimulation provide
a unique opportunity to investigate the functional integrity and
magnitude of brain processing pathways. Expressing the
ability of the human brain to discriminate, classify, and
memorize the significance of exogenous stimuli, event-related
potentials (ERPs) have been used as a marker of cognitive
function in patients with psychiatric and neurological
disorders. The electrical waveforms generated can be divided
into late and early components, and the waveforms are
designated by their polarity (P-positive, N-negative) and
latency (timing of peak) after stimulus onset. Additionally, the
amplitude – the size of the voltage difference between the
component peak and a prestimulus baseline – is also
quantified. Auditory, somatosensory, and visual ERPs have
been evaluated in patients with FM in a few studies.
Among the ERPs evaluated to date, the P300 potential (most
commonly generated by an auditory consciously attended
stimuli) appears to be the most promising to differentiate FM
patients from control individuals. The P300 wave is a late
cortical neuropsychological event, the latency of which
reflects the information processing speed and the amplitude
of which expresses memory functions. A reduced P300
amplitude during an auditory discriminated-task paradigm has
been significantly noted in FM patients as compared with
control individuals in three cross-sectional studies by two
different groups [46-48] (Table 7). All three studies also
evaluated the P300 latency, but only the largest study by
Alanoglu and colleagues noted an increase in P300 latency,
a finding that may have not been found in the prior studies
due to lack of power [46]. In the one of these three studies by
Ozgocmen and colleagues that performed ERPs before and
after treatment, 8 weeks of sertraline treatment led to an
increase in the P300 magnitude [48].
These studies generally failed to show an association
between the ERP findings and symptom severity, although
Arthritis Research & Therapy    Vol 10 No 4 Dadabhoy et al.
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Table 3
Pain pressure thresholds and fibromyalgia (FM): part 2
Number of 
Year of  Number of  control 
Reference study FM patients individuals QST QST method Findings
Petzke and  2005 43 28 PPT: CP ASC and  FM patients report greater pain intensity but 
colleagues [123] random less relative unpleasantness compared with 
HC
Giesecke and  2004 16 11 HC,  PPT: CP ASC and  FM and CLBP with decreased PPT
colleagues [124] 11 CLBP random
Giesecke and  2003 97 n/a PPT: CP ASC and  FM subgroups: high and low tenderness. 
colleagues [125] random High or low control over pain correlated with 
cognitive and mood factors
Petzke and  2003 43 28 PPT: CP,  ASC and  FM decreased PPT, suprathresholds. 
colleagues [28] suprathreshold random Ratings from random method were 
consistently higher than those of the ASC 
method, possibly due to perceived lack of 
perceived control
Petzke and  2003 39 FM,  28 no pain,  PPT: CP  ASC and  Random method independent of psychological 
colleagues [24] 6 CWP,  3 pain and TP random state. ASC correlated more with psychological 
3 regional state
Gracely and  2002 16 16 PPT: CP ASC and  FM with decreased PPT
colleagues [126] random
Chang and  2000 11 IBS +  11 IBS,  PPT: TP  ASC and  In random method, IBS + FM with more 
colleagues [27] FM 10 HC and CP random decreased PPT than IBS, but not HC. IBS with 
higher PPT than HC. In ASC, IBS similar PPT 
to HC
Bendtsen and  1997 25 25 PPT: TP  Random FM with left shift in response 
colleagues [127] and CP,  function for stimuli applied to tender point 
suprathreshold (trapezius m) only, no difference in CP 
compared with HC
ASC, ascending; CLBP, chronic low back pain; CP, control point; CWP, chronic widespread pain; HC, healthy control individuals; IBS, irritable
bowel syndrome; PPT, pain pressure thresholds; QST, quantitative sensory testing; TP, tender point.Available online http://arthritis-research.com/content/10/4/211
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Table 4
Heat pain threshold, cold pain threshold, and electrical stimuli in fibromyalgia
Number Number 
Year of  of FM  of control  QST 
Reference study patients individuals QST method Findings
Petzke and  2003 43 28 HPT,  ASC and  FM decreased HPT, suprathresholds. Pain ratings 
colleagues [28] suprathreshold RAN from RAN were consistently higher than ASC, 
possibly due to perceived lack of perceived control
Gibson and  1994 10 10 WT and  ASC and  FM decreased HPT, no difference in WT
colleagues [29] HPT  RAN
Staud and  2005 11 12 Suprathreshold:  ASC Increased thermal pain ratings after exercise 
colleagues [102] affected and CP (opposite of HC)
Geisser and  2003 20 20 HPT, WT ASC FM with decreased HPT. Higher intensity and 
colleagues [108] unpleasantness for non-noxious stimuli
Kosek and  1997 10 10 CT, WT,  ASC FM decreased CT in forearm. FM decreased CPT 
Hansson [30] CPT, HPT and HPT. No difference in WT
Lautenbacher and  1997 25 26 HPT ASC FM had decreased HPT
Rollman [34]
Kosek and  1996 10 10 CT, WT,  ASC FM decreased HPT, CPT. FM had decreased WT 
colleagues [31] CPT, HPT only at TP
Lorenz and  1996 10 10 HPT ASC FM decreased HPT
colleagues [128]
Lautenbacher and  1994 26 26 HPT ASC FM decreased HPT, no difference in WT
colleagues [120]
Lautenbacher and  1997 25 26 Electrical ASC No difference in electrical detection/PT
Rollman [34]
Lautenbacher and  1994 26 26 Electrical –  ASC FM decreased electrocutaneous only at TP, not 
colleagues [120] CP and TP control points
Arroyo and  1993 10 10 Electrical detection,  ASC No difference in electrical detection, FM 
Cohen [129] suprathreshold decreased electrical tolerance
ASC, ascending; CP, control point; CPT, cold pain threshold; CT, cold perception threshold; FM, fibromyalgia; HC, healthy control individuals;
HPT, heat pain threshold; PT, pain threshold; QST, quantitative sensory testing; RAN, random; TP, tender point; WT, warmth perception threshold.
Table 5
Diffuse noxious inhibitory controls (DNIC) in fibromyalgia (FM)
Number of  Heterotopic 
Year of  Number of  control  Test stimuli  conditioning 
Reference study FM patients individuals (noxious stimuli) noxious stimuli Findings
Julien and  2005 30 30 HC,  Water bath, cold,  Water bath, cold,  Diminished DNIC in FM patients, not 
colleagues [32] 30 CLBP noxious noxious CLBP
Staud and  2003 11 22 females,  Wind up Water bath, heat,  Diminished DNIC in female HC and 
colleagues [33] 11 males noxious female FM patients
Kosek and  1997 10 10 CT, WT, HPT, CPT Tourniquet Diminished DNIC in FM patients
Hansson [30]
Lautenbacher  1997 25 26 Electrical pain  Thermode tonic  Diminished DNIC in FM patients
and Rollman [34]  threshold cold thermal, noxious 
and non-noxious
Electrical detection No difference
CLBP, chronic low back pain; CT, cold perception threshold; CPT, cold pain threshold; HC, healthy control individuals; HPT, heat pain threshold;
WT, warmth perception threshold.Arthritis Research & Therapy    Vol 10 No 4 Dadabhoy et al.
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Table 6
Neural imaging in fibromyalgia (FM)
Number of 
Year of  Number of  control  Neural 
Reference study FM patients individuals imaging Description QST Findings
Giesecke and  2005 7 7 MDD/FM,  fMRI QST evoked  Pressure pain  Clinical pain intensity – 
colleagues [37] 7 HC rCBF association  MRS associated with increased rCBF 
to depression of insula bilaterally, contralateral 
ACC, prefrontal cortex. 
Symptoms of depression – not 
associated with increased rCBF 
of SI, SII; associated amygdala 
and contralateral anterior insula
Gracely and  2004 15 high  14 low  fMRI QST evoked  Pressure pain  Both low and high with increased 
colleagues [40] catastrophizers catastrophizers rCBF association  MRS rCBF in contralateral insula, SI, 
to catastrophizing  SII, inferior parietal lobule and 
thalamus, ipsilateral S1, 
cerebellum, posterior cingulate 
gyrus, and superior and inferior 
frontal gyrus. High catastrophizers 
with unique activation in 
contralateral anterior ACC, 
contralateral ipsilateral lentiform
Giesecke and  2004 16 11 HC,  fMRI QST evoked  Pressure pain  In CLBP and FM patients, QST 
colleagues [124] 11 CLBP rCBF MRS (equal pressure) increased rCBF 
of contralateral SI and SII, inferior 
parietal lobule, cerebellum, and 
ipsilateral SII. In HC, QST (equal 
pressure) activation of 
contralateral SII. Equal evoked 
equal pain associated with similar 
activation
Koeppe and  2004 ? None fMRI Injection of 5-HT-3  n/a In FM patients, topisetron 
colleagues [39] receptor antagonist  treatment reduced rCBF of SI, 
(topisetron) rCBF contralateral posterior insula, 
ACC
Cook and  2004 9 9 HC fMRI QST evoked  Nonpainful and  In FM, nonpainful heat increased 
colleagues [38] activation of rCBF painful heat, 47°C rCBF in prefrontal, supplemental 
motor, insular, and ACC as 
compared with HC. In FM 
patients, painful heat increased 
activity in contralateral insular 
cortex as compared with HC
Gracely and  2002 16 16 HC fMRI QST evoked  Pressure pain  Common areas of evoked equal 
colleagues [126] activation of rCBF MRS, neutral site pain increased rCBF including 
contralateral SI, inferior parietal 
lobule, SII, superior temporal 
gyrus (STG), insula, putamen, and 
ipsilateral cerebellum. Decreased 
rCBF in ipsilateral SI. In HC, QST 
(equal pressure) activated 
ipsilateral STG and precentral 
gyrus
Yunus and  2004 12 7 HC PET Resting rCBF n/a No difference
colleagues [130]
Chang and  2003 10 IBS +  10 IBS PET QST evoked  Noxious visceral  In IBS patients, noxious visceral 
colleagues [131] FM activation of rCBF and somatic  stimuli evoked increased rCBF 
pressure  increase in middle subregion of 
the ACC. In IBS + FM patients, 
somatic stimuli evoked greater 
rCBF in middle subregion of the 
ACC extending to ACC and the 
thalamus
Continued overleafthere was an association noted with the total myalgic score.
Although the change in the P300 potential after sertraline
treatment was attractive, the authors agreed that – given the
corresponding significant clinical improvement in pain,
fatigue, or depression – the mechanism for the change
remained unclear, and they acknowledged it may represent
regression to the mean. Larger studies by different groups
with an attention to standardizing methods are essential prior
to mainstream use of this marker.
In contrast to auditory potentials, there are few and varied
studies evaluating somatosensory and visual ERPs. The
assorted protocols used in the studies investigating somato-
sensory and visual ERPs may have contributed to the lack of
consistently demonstrated differences in FM and normal
individuals. The lack of an established standardized metho-
dology makes direct comparison difficult and may limit the
evidence of reproducibility.
Sleep and activity
In addition to pain, other symptoms very commonly seen in
FM include disturbed sleep and poor function. Sleep logs
and polysomnography have consistently confirmed patient
reports of hypersomnolence [49,50]. Using polysomno-
graphy, investigators have correlated hypersomnolence with
poor sleep quality by demonstration of fewer sleep spindles,
an increase in the cyclic alternating pattern rate, or poor
sleep efficiency [51-53]. Sleep abnormalities are rarely
shown to correlate with symptoms in FM, however, and many
investigators anecdotally feel as though even identifying and
treating specific sleep disorders often seen in FM patients
(for example, obstructive sleep apnea, upper airway resis-
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Table 6
(Continued)
Number of 
Year of  Number of  control  Neural 
Reference study FM patients individuals imaging Description QST Findings
Wik and  2006 8 None PET QST evoked  Acute pain In FM patients, frontal and parietal 
colleagues [132] activation of rCBF cortical activation during acute 
pain compared with rest (as 
expected). Reduced rCBF in 
retrosplenial cortex (evaluative 
processing)
Wood and  2007 11 11 HC PET QST evoked  Nonpainful and  In FM patients, lack of dopamine 
colleagues [41] binding of D2/D3  painful saline  release in basal ganglia compared 
ligand injection with HC during painful stimuli. In 
HC, amount of dopamine release 
correlated with amount of 
perceived pain; in FM patients, no 
such correlation observed
Adiguzel and  2004 14 None SPECT Amitriptyline  n/a Increased rCBF in bilateral 
colleagues [42] (3 months) resting  hemithalami after amitriptyline. No 
rCBF correlation between symptoms 
and findings
Gur and  2002 19 20 HC SPECT Resting rCBF n/a Increased rCBF in caudate 
colleagues [45] nucleus. FM patients with less 
depression had increased uptake 
in pons
Kwiatek and  2000 17 22 HC SPECT  Resting rCBF n/a Reduced rCBF in right thalamus 
colleagues [43] and potine tegmentum, no 
reduction in left thalamus, or 
caudate nucleus. No correlation 
between symptoms and findings
Mountz and  1995 10 7 HC SPECT  Resting rCBF n/a Reduced rCBF in bilateral 
colleagues [44] hemithalami and caudate nucleus 
correlated with low pain threshold 
No correlation between 
symptoms and findings
ACC, anterior cingulate cortex; CLBP, chronic low back pain; fMRI, functional magnetic resonance imaging; HC, healthy control individuals;
5-HT-3, 5-hydroxytryptamine 3; IBS, irritable bowel syndrome; MDD, major depression disorder; MRS, multiple random staircase; n/a, not
applicable; PET, positron emission tomography; QST, quantitative sensory testing; rCBF, regional cerebral blood flow; SI, somatosensory cortex I;
SII, somatosensory cortex II; SPECT, single-photon emission computed tomography.tance, restless leg or periodic limb movement syndromes)
does not necessarily lead to improvements in the core
symptoms of FM.
Actigraphy
A method of motion assessment that infers sleep and
wakefulness from the presence of limb movements, actigraphy
is increasingly being used as a surrogate marker for both sleep
and activity. The actigraph typically combines a movement
detector and memory storage on a watch-like device. The
device can be worn on the wrist or the ankle continuously for
long periods of time. Sleep-pattern measures available via
actigraphy analyses include sleep latency, the wake time after
sleep onset, and the total sleep time; sleep architecture cannot
be measured, as with polysomnography. Compared with
polysomnography, however, actigraphy is less expensive, less
invasive, and more conducive to repeated measures, resulting
in extensive use in intervention studies [54].
Actigraphy is being increasingly used in FM studies and
appears promising, but has not yet proven adequately
sensitive to stand alone in clinical evaluation or treatment
trials [50,55,56]. As a measure of sleep quality there have
been inconsistent actigraphy results, with one group noting
increased levels of activity at night in FM (also noted in
patients with major depression) [55] and another group
noting no difference [50]. Edinger and colleagues used
actigraphy as an outcome measure in an intervention trial
comparing cognitive behavior therapy intervention with sleep
hygiene and usual care in the treatment of insomnia [57].
Deriving an actigraphic improvement criterion, the investi-
gators showed a greater number of patients receiving
cognitive behavior therapy had clinically significant improve-
ment in the total wake time compared with sleep hygiene
therapy. No statistical difference between cognitive behavior
therapy and usual care was able to be demonstrated, even
though a statistical difference between the groups was
shown using sleep log data in the same study.
As an objective measure of functional status, actigraphy
might hold more promise as a surrogate outcome measure,
because it allows the direct recording of activity levels, rather
than relying on patient self-report [58]. Kop and colleagues
demonstrated that although patients with FM have 36-Item
Short Form health survey scores nearly two standard
deviations below the population average, they have the same
average activity level as a group of sedentary control
individuals [58]. The FM patients had much lower peak
activity levels, however, suggesting that the problems in
function that FM patients report might be more due to an
inability to rise to the intermittent demands of day-to-day life
than due to overall reduced function.
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Table 7
Evoked potentials in fibromyalgia (FM)
Number of 
Year of  Number of  control Evoked 
Reference study FM patients individuals potential Paradigm EP evaluated Findings
Alanoglu and  2005 34 22 Auditory Auditory  P300 wave FM reduced P300 amplitude and 
colleagues [46] discriminated  prolonged latency. No correlation 
task paradigm  between EP findings, pain scores, 
and quality of life measurements
Yoldas and  2003 11 10 Auditory Auditory  P300 wave FM reduced P300 amplitude, but 
colleagues [47] discriminated  no difference in potential latency. 
task paradigm P300 latency negatively 
correlated with total myalgic 
scores and the control point 
scores. P300 amplitude 
correlated with PPT and total 
myalgic scores. No correlation in 
amplitude or latency with 
depression or anxiety.
Ozgocmen and  2003 13 10 Auditory Auditory  P300 wave FM reduced P300 amplitude, but 
colleagues [48] discriminated  no difference in potential latency 
task paradigm ~ at baseline. Sertraline treatment 
before and after  resulted in increase in potential 
sertraline  amplitude by 8 weeks without 
treatment  change in latency. No correlation 
(8 weeks) between EP findings, fatigue and 
pain scores, but correlated to 
total myalgic scores
EP, evoked potential; PPT, pain pressure thresholds.Stress–response systems and 
sex hormones
The theoretical link between stress–response systems and
symptom expression is supported by studies demonstrating
alterations of the hypothalamic–pituitary–adrenal axis and
the autonomic nervous system in FM. Probing different
aspects of the stress systems is underway to uncover
objective ways to identify persons at risk or to identify
reproducible abnormalities. One group clearly with
increased susceptibility is women. Investigators hypothesize
a potential effect of sex hormones on the stress response to
partly explain the female predominance seen in FM, but this
connection has not yet been specifically examined in FM
patients [59].
Hypothalamic–pituitary–adrenal axis
In basal and diurnal cortisol studies, the most consistently
found measure is a flattened diurnal plasma cortisol level
with an elevated trough, found in three of four cross-
sectional studies by two out of three groups [60-62]
(Table 8). Studies evaluating basal plasma cortisol levels,
salivary basal and diurnal cortisol levels, and urinary cortisol
levels have shown inconsistent results, but they generally
demonstrate normal to reduced basal levels. Since atypical
depression can show a reduced cortisol level, biopsycho-
logical factors that influence cortisol levels may be contri-
buting to the inconsistent results currently found in the
literature [63]. These factors need to be better elucidated
and accounted for in future studies. Nonetheless, a flattened
diurnal cortisol level is a promising objective measure.
Evaluation of other components of the hypothalamic–pituitary–
adrenal axis has been relatively unrevealing. Basal and diurnal
adrenocorticotropic hormone shows no difference in FM
patients versus healthy control individuals [62,64,65]
(Additional file 1). Provocative hypothalamic–pituitary–adrenal
studies utilizing the cosyntropin test have shown inconsistent
results [62,66-68] (Additional file 2).
Results of the dexamethasone suppression test have been
reported in a number of studies by different groups, and the
results reveal normal to high levels of cortisol following
infusion of the corticosteroid [60,64,66,69,70] (Additional
file 3). Depression also typically follows a pattern of resis-
tance to the dexamethasone test, and therefore is a
confounding factor in a large number of these evaluations.
Studies have also been completed to assess the cortisol
response to exogenous corticotropin-releasing hormone or
endogenous activators of corticotropin-releasing hormone
(that is, hypoglycemia, IL-6) in FM. Investigators found normal
to reduced cortisol levels in patients with FM after an
increase in corticotropin-releasing hormone, but these results
were not reproduced in other similar studies. Further investi-
gation taking into account psychological factors as well as
doses of different drugs will be prudent.
Autonomic reactivity
Tilt table testing and heart rate variability have been evaluated
in patients with FM. The consistent and reproducible finding
of lower heart rate variability in FM patients compared with
control individuals (in three cross-sectional studies by two
different groups) makes it a more useful measure than tilt
table testing [71-73]. An abnormal drop in blood pressure or
an excessive rate of syncope during tilt table testing has been
noted in two out of three cross-sectional studies completed
by three different groups [74-76]. One study noted no
difference in normal individuals and control individuals using
univariate analysis [76]. Moreover, recent findings also
suggest that aberrations in heart rate variability may
predispose to fibromyalgia symptoms [77,78], possibly
identifying patients at risk.
Sex hormones
FM syndrome is more prevalent in women than in men,
suggesting a role of sex hormones in the pathophysiology of
FM [79]. To date, two studies have failed to show an
association between sex hormones and pain sensitivity
[79,80]. The reason for a female predominance in FM is
complex and warrants further investigation.
Serologic and biochemical abnormalities
Physicians from multiple disciplines have used simple blood
tests to diagnose and evaluate treatment for various
diseases. Scientists have similarly evaluated a number of
compounds in the serum and cerebrospinal fluid of patients
with FM to find a comparable marker of disease or disease
activity. Despite the effort to find easily accessible measures,
no clinically suitable tests have yet been appropriately
validated for FM.
Autoantibodies
The search for representative autoantibodies is a predictable
step for a disease like FM, often evaluated by rheuma-
tologists and coexisting with autoimmune diseases. Anti-
serotonin antibody, antiganglioside antibody, and anti-
phospholipid antibody have been shown to be different in
FM patients and control individuals, but the applicability of
these findings is not yet clear [81] (Table 9). Antiserotonin
antibody has been shown to be increased in FM in three
cross-sectional studies by two different groups [81-83].
Antiganglioside antibody and antiphospholipid antibody have
each been shown to be increased in FM in two cross-
sectional studies by the same group [81,82]. A different
group evaluating antiganglioside antibody in a third cross-
sectional study was unable to reproduce the results [83].
Antithromboplastin antibody [83], antipolymer antibody [84],
and anti-68/48 kDa and anti-45kDa [85] have each been
evaluated in one cross-sectional study and have shown
increased levels in FM. A review of the literature demon-
strates that antinuclear antibodies, antithyroid antibodies,
antisilicone antibodies, and antiglutamic acid decarboxylase
are not informative in FM.
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Table 8
Basal and diurnal cortisol and fibromyalgia (FM)
Number of 
Year of  Number of  control 
Reference study FM patients individuals Measured (plasma) Findings
McCain and  1989 20 20 RA Plasma cortisol Normal peak, elevated trough, flattened diurnal compared 
Tilbe [60] to RA
Crofford and  1994 7 7 Plasma cortisol Normal peak, elevated trough, flattened diurnal
colleagues [133]
Crofford and  2004 13 12 FMS +  Plasma cortisol  Delay in rate of decline in FM, elevated cortisol in late 
colleagues [61] CFS, 15 CFS period in FM, flattened diurnal, lower O/N cortisol in CFS
Adler and  1999 15 13 Plasma cortisol –  Normal, normal diurnal
colleagues [62] total and free
Korszun and  1999 9 9 HC,  Plasma cortisol Normal
colleagues [134] 8 CFS
Malt and  2002 22 13 Plasma cortisol Normal
colleagues [135]
Valkeinen and  2005 13  13 Plasma cortisol Normal
colleagues [136]  (60 years  (59 years
old) old)
Griep and  1993 10 10 Plasma cortisol Normal
colleagues [64]
Gur and  2004 63  38 Plasma cortisol Reduced
colleagues [137] (<35 years (<35 years
old) old)
Gur and  2004 68 46 HC,  Plasma cortisol Reduced in FM with high BDI scores (>17), not in those 
colleagues [63] 62 CFS with low BDI. Reduced in CFS
Griep and  1998 40 14 HC,  Plasma cortisol Reduced
colleagues [66] 28 CLBP
Lentjes and  1997 40 14 HC,  Plasma cortisol – Reduced total cortisol in FM only, Normal free cortisol in 
colleagues [138] 28 CLBP total and free FM, CLBP
Riedel and  1998 16 17 Plasma cortisol Elevated
colleagues [65]
Catley and  2000 21 22 HC,  Salivary cortisol  Elevated, normal diurnal
colleagues [139] 18 RA 6 times/day
McClean and  2005 20 16 Salivary cortisol  Normal, normal diurnal strong relationship between current 
colleagues [140] 5 times/day pain symptoms and cortisol levels at waking and 1 hour 
after waking. No relationship between fatigue and stress
Weissbecker  2006 85 n/a Salivary cortisol  Flattened diurnal, greater cortisol responses to awakening 
and colleagues [141] 6 times/day in FM with history psychological, physical abuse
Dedert and  2004 91 n/a Salivary cortisol  Flattened diurnal on those with low religiosity
colleagues [142] 5 times/day
Sephton and  2003 50 n/a Salivary cortisol  Higher log-transformed mean salivary cortisols associated 
colleagues [143] 5 times/day with better memory
Adler and  1999 15 13 24-hour urinary cortisol  Normal
colleagues [62]
Maes and  1998 ? PTSD,  24-hour urinary cortisol  Normal
colleagues [144] depression
Torpy and  2000 13 8 24-hour urinary cortisol  Normal (trend toward reduced)
colleagues [145]
Crofford and  1994 12 10 24-hour urinary cortisol  Reduced (no difference between depressed and non 
colleagues [133] depressed)
Lentjes and  1997 40 14 HC,  24-hour urinary cortisol  Reduced in FM and CLBP
colleagues [138] 28 CLBP
Griep and  1998 40 14 HC,  24-hour urinary cortisol  Reduced
colleagues [66] 28 CLBP
BDI, Beck Depression Inventory; CFS, chronic fatigue syndrome; CLBP, chronic low back pain; FMS, fibromyalgia syndrome; HC, healthy control
individuals; PTSD, post-traumatic stress disorder; RA, rheumatoid arthritis.The nonspecific increase in antibodies to a number of
antigens may be a nonspecific finding that arises from a
subtle shift in immune function in this spectrum of illness. In
the closely related chronic fatigue syndrome, investigators
have noted a shift from a T1 to a T2 immune response, which
would be expected to lead to increased production of
nonspecific antibodies. Any antibody or autoantibody
proposed as either a diagnostic test for FM or a biomarker of
FM must therefore be carefully tested using various control
individuals to ensure its authenticity.
Neuropeptides
Substance P is a neuropeptide released in spinal fluid when
axons are stimulated. Four different cross-sectional studies by
various groups in FM patients noted an elevation of
substance P in cerebrospinal fluid [86-89]. In contrast, a
normal substance P level has been noted in the cerebrospinal
fluid of patients with chronic fatigue syndrome [90]. Although
these results appear promising, elevated substance P is not
specific for FM but rather has been shown to occur in other
pain states such as chronic, daily headaches and chronic
neck or shoulder pain associated with whiplash injury
[91,92]. A high level of substance P therefore seems to be a
biological marker of the presence of chronic pain.
Nerve growth factor and calcitonin gene-related peptide are
additional neuropeptides that have been evaluated in FM.
Nerve growth factor was shown in one study to have
increased levels in FM and not in FM/rheumatoid arthritis
overlap, therefore presenting inconclusive results [93].
Cerebrospinal fluid and serum calcitonin gene-related
peptide have been studied and not found to be different in
FM patients and control individuals [94,95].
Biochemicals and cytokines
The amino acid tryptophan and the cytokine IL-8 have both
been shown to be different in patients compared with control
individuals in a couple of studies, but neither have been
evaluated in longitudinal studies [96-98]. A low tryptophan
level has been found in two of three studies by three different
groups [96,99,100]. IL-8 has been consistently demonstrated
in three studies by two different groups [97,98,101]. Moreover,
IL-8 has been shown to correlate with symptoms of FM and not
to be associated with depressed FM [98]. Serum IL-6 was
evaluated and found to be normal in FM patients [98,101].
Muscle abnormalities
Despite the interest and investigation for objective peripheral
muscle abnormalities, the results have remained variable and
have not yet been reproduced by different groups.
Additionally, there is great heterogeneity in the methods
evaluating for objective muscle abnormalities that render a
complete review of the data beyond the scope of the present
study. To dissect out possible useful objective measures,
further investigations are necessary, preferably utilizing non-
invasive procedures.
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Table 9
Autoantibodies and fibromyalgia (FM)
Year of  Number of  Number of 
Reference study FM patients control individuals Objective measure Findings
Klein and colleagues [82] 1992 50 ?HC Antiserotonin Increased in FMS
Antiganglioside Increased in FMS
Antiphospholipid Increased in FMS
Klein and Berg [81] 1995 100 42 CFS, ?HC Antiserotonin Increased in CFS and FMS
Antigangliosides Increased in CFS and FMS
Antiphospholipid Increased in CFS and FMS
Werle and colleagues [83] 2001 203 64 Antiserotonin Increased
Antithromboplastin Increased
Antiganglioside No  difference
Gm1 No difference
Wilson and colleagues [84] 1999 47 16 OA,12 RA, banked sera,  Antipolymer antibody Increased in antipolymer 
15 myositis, 30 RA,  antibodies, higher in severe 
30 SLE, 30 SSc versus mild
Nishikai and colleagues [85] 2001 125 114 CFS, ?psych, ?CTD Anti-68/48 kDa Increased in FMS and CFS
Anti-45 kDa Increased in FMS and CFS
CFS, chronic fatigue syndrome; CTD, connective tissue disease; FMS, fibromyalgia syndrome; HC, healthy control individuals; OA, osteoarthritis;
RA, rheumatoid arthritis; SLE, systemic lupus erythmatosus; SSc, systemic sclerosis.Conclusion
Except for psychophysical pain testing, no objective measure
has been appropriately evaluated and shown to improve with
improvements in clinical status in a longitudinal study, and
thus to qualify as a biomarker (see Table 10 for summary).
These tests are not, however, entirely objective. Of the
objective tests, those that hold the most promise as
biomarkers are probably tests that directly assess elements
of neural function, such as functional neuroimaging, ERPs,
and DNIC. An effort by different groups to systematically
evaluate these measures in research trials to obtain useful,
comparable results will be vital for ongoing progress in
outcome research. There will be an ongoing need to identify
biomarkers for future studies that have reproducibility and
predictive value, practicability, and biological and temporal
relevance in FM.
Additional files
The following Additional files for this article are available
online:
Additional file 1 is an Excel file containing a table that
presents studies of basal and diurnal adrenocorticotropic
hormone and fibromyalgia. See http://arthritis-research.com/
content/supplementary/ar2443-s1.xls
Additional file 2 is an Excel file containing a table that
presents studies of the cosyntropin test and fibromyalgia.
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Table 10
Summary of findings for objective markers
Objective marker Findings
Genetics Polymorphisms in catecholamine o-methyl transferase have been noted in some ethnic groups but not others; 
dopamine 4 receptor findings have not been replicated or refuted as compared with other polymorphisms
Tender point counts or index Multiple studies suggesting utility. The tender point count and the tender point index may be influenced by 
cognitive and emotional aspects of pain, and therefore may be biased
Pressure pain threshold Multiple studies suggesting utility. The pressure pain threshold may be influenced by cognitive and emotional 
aspects of pain, which may be minimized by utilizing a random pressure paradigm
Heat and cold pain threshold Consistently different in patients versus control individuals but not shown to be correlated with changes in 
clinical pain
Diminished diffuse noxious  Four cross-sectional studies by different groups suggest utility. Needs further exploration with standardized 
inhibitory controls  methods, longitudinal studies
Functional neural imaging Multiple studies suggesting utility. May be influenced by cognitive aspects of pain. Longitudinal studies 
needed
Event-related potentials Reduced P300 amplitude has been noted in three cross-sectional studies by two different groups. Larger 
studies with standardized methods are necessary. Longitudinal studies needed
Sleep logs and polysomnography Confirm reports of hypersomnolence, but no changes are pathognomonic of or specific for fibromyalgia
Actigraphy Inconsistent measure of sleep quality. Report suggesting utility in measuring functional status. Larger, 
longitudinal studies needed
Hypothalamic–pituitary– Flattened diurnal cortisol noted in three of four cross-sectional studies by two of three groups. Need to 
adrenal axis explore influence of biopsychosocial factors. Longitudinal studies needed
Autonomic reactivity Lower heart rate variability noted in three cross-sectional studies by two different groups. May predispose to 
condition. Longitudinal studies needed
Autoantibodies Antiserotonin antibody noted to be increased in three cross-sectional studies by two different groups. 
Stringent controls necessary prior to determining utility. Longitudinal studies needed
Neuropeptides Substance P noted to be increased in cerebrospinal fluid in four cross-sectional studies by various groups. 
Potential nonspecific marker of chronic pain
Biochemical and cytokines Low tryptophan and elevated IL-8 noted. Longitudinal studies needed
Muscle abnormalities No clear and reproducible abnormality. Additional studies with standardized methods needed
This review is part of a series on 
Biology and therapy of fibromyalgia
edited by Leslie Crofford.
Other articles in this series can be found at 
http://arthritis-research.com/articles/
review-series.asp?series=ar_fibromyalgiaSee http://arthritis-research.com/content/supplementary/
ar2443-s2.xls
Additional file 3 is an Excel file containing a table that
presents studies of the dexamethasone test and fibromyalgia.
See http://arthritis-research.com/content/supplementary/
ar2443-s3.xls
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